Novo Nordisk gets sued by its own shareholders for allegedly lying about how well people could tolerate CagriSema. The drug disappointed in trials. The stock tanked. Billions evaporated. Now the investors who bought shares in a Danish pharmaceutical company want their money back because—and I'm reading this correctly—they trusted management guidance.
CagriSema was supposed to be the next-generation weight-loss miracle. Turns out it made people feel like sh*t at the doses that actually worked. Clinical trials revealed this. The market responded by deleting Novo's market cap like a drunk text. Shareholders claim they were misled about tolerability data. They filed suit. They want damages. They will almost certainly settle for seventeen dollars and a coupon for Wegovy.
Here's what kills me. These are institutional investors. Sophisticated money. The kind of people who have Bloomberg terminals and ergonomic standing desks and opinions about the Fed's dot plot. They bought a biotech stock trading at a valuation that assumed every human with a BMI over 22 would inject themselves twice weekly until the heat death of the universe. Then one clinical readout came in softer than expected and they acted shocked. Shocked that a company hyped its pipeline. Shocked that Phase 3 data didn't match the investor deck. Shocked that forward guidance from management might have been—stay with me here—optimistic.
The lawsuit alleges material misrepresentation. It alleges securities fraud. It alleges Novo knew CagriSema had tolerability issues and buried the lede. Maybe they did. Maybe they didn't. Either way, the shareholders who are suing today were buying hand over fist six months ago when the chart was up and to the right.
They didn't need a lawsuit then. They needed one the second price discovery worked against them. That's not investing. That's just suing your way out of a bad entry.
Photo by on Unsplash
Leave a Comment